Consensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak

dc.authorid0000-0003-4273-5518
dc.authorid0000-0001-9419-8713
dc.authorid0000-0002-6869-6070
dc.authorid0000-0002-4378-5907
dc.authorid0000-0002-0798-4554
dc.authorid0000-0002-7796-0750
dc.authorid0000-0002-2052-6072
dc.contributor.authorYalcinkaya, Ebru Yilmaz
dc.contributor.authorKaradağ Saygi, Evrim
dc.contributor.authorOzyemisci Taskiran, Ozden
dc.contributor.authorCapan, Nalan
dc.contributor.authorKutlay, Sehim
dc.contributor.authorSonel Tur, Birkan
dc.contributor.authorOzlem, E. L.
dc.date.accessioned2025-05-10T19:53:04Z
dc.date.issued2021
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractSpasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared and adapted to the Delphi technique by PMR specialists. Then they were asked to the physicians experienced in BoNT injections (PMR specialist, pediatric orthopedists, and pediatric neurologists) or COVID-19 (pediatric infectious disease, adult infectious disease). In conclusion, the experts agree that conservative management approaches for spasticity may be the initial steps before BoNT injections. BoNT injections can be administered to children with CP with appropriate indications and with necessary precautions during the pandemic.
dc.identifier.doi10.3906/sag-2009-5
dc.identifier.endpage392
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue2
dc.identifier.pmid33350298
dc.identifier.scopus2-s2.0-85104050977
dc.identifier.scopusqualityQ1
dc.identifier.startpage385
dc.identifier.trdizinid483524
dc.identifier.urihttps://doi.org/10.3906/sag-2009-5
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/483524
dc.identifier.urihttps://hdl.handle.net/20.500.14730/12623
dc.identifier.volume51
dc.identifier.wosWOS:000646281600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal of Medical Sciences
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.subjectBotulinum toxin
dc.subjectcerebral palsy
dc.subjectCOVID-19
dc.subjectpandemic
dc.subjectspasticity
dc.titleConsensus recommendations for botulinum toxin injections in the spasticity management of children with cerebral palsy during COVID-19 outbreak
dc.typeReview

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
12623.pdf
Boyut:
145.44 KB
Biçim:
Adobe Portable Document Format